The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease
Abstract
OBJECTIVE: To investigate the effect of different antithyroid drug (ATD) regimens on relapse rates of Graves' disease, and to look for predictors of relapse. DESIGN AND METHODS: In a prospective two-way factorial randomized clinical trial, 218 patients with Graves' disease were assigned to ATD combined with l-thyroxine (l-T(4)) or ATD alone for 12 Months. After discontinuation of antithyroid therapy, each group was stratified to either 12 Months further treatment with l-T(4) or no treatment. Clinical and biochemical assessments were carried out before treatment, after 3 and 6 weeks, and every third Month for 12 Months. If the patients lacked symptoms of relapse, laboratory tests were performed every third Month for the second Year, and thereafter annually. RESULTS: The proportion of all patients with relapse was 47.7% 2 Years after withdrawal of ATD. There was no difference in relapse rates between the treatment groups (P=0.217, log--rank test). Smokers had a higher relapse rate than non-smokers (58.4% vs 38.8%, P=0.009). Patients who were thyrotropin-receptor antibody (TRAb) positive after 12 Months of antithyroid therapy had a higher relapse rate than those who were negative (72.5% vs 36.8%, P<0.0001). Similarly, relapse was more frequent (55.5%) in patients having large goiter compared with subjects with small goiter (36.3%, P=0.0007). CONCLUSIONS: Relapse rates of Graves' disease were independent of ATD regimen whether followed by l-T(4) therapy or not. Smoking, large goiter and presence of TRAb at the end of ATD therapy were strong predictors of relapse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A lower remission rate has been described in men, smokers (especially men), and those with large goiters ( ‡80 g) (165-169).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [167]
In the citing paper
“In patients with negative TRAb, relapses tend to occur relatively later than those that develop in patients whose MMI is stopped when TRAb is still positive (171,176), although 5% occurred within the first 2 months in one study (167).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [167]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Autoimmune Thyroid Disease: Further Developments in Our Understanding*
Weetman, A. P., & McGregor, A. M. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-6-788 · Cited by 656
Smoking and thyroid disorders--a meta-analysis
Vestergaard, P. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460153 · Cited by 308
VITTI, P., RAGO, T., CHIOVATO, L., PALLINI, S., SANTINI, F., FIORE, E., ROCCHI, R., MARTINO, E., & PINCHERA, A. (1997) · Thyroid · doi:10.1089/thy.1997.7.369 · Cited by 293
Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism
Allahabadia, A., Daykin, J., HOLDER, R. L., Sheppard, M. C., Gough, S. C. L., & Franklyn, J. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6430 · Cited by 286
Administration of Thyroxine in Treated Graves' Disease
Hashizume, K., Ichikawa, K., Sakurai, A., Suzuki, S., Takeda, T., Kobayashi, M., Miyamoto, T., Arai, M., & Nagasawa, T. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241403 · Cited by 214
Allannic, H., Fauchet, R., Orgiazzi, J., Orgiazzi, A., GENETET, B., LORCY, Y., GUERRIER, A. M. L., Delambre, C., & Derennes, V. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-675 · Cited by 192
Feldt‐Rasmussen, U., Schleusener, H., & Carayon, P. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.1.8288723 · Cited by 184
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–132 of 132
Buldygina, Y. V., Strafun, L. S., Terekhova, H. М., Shlyakhtych, S. L., & Pankiv, V. І. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.2.2019.166111 · Cited by 3
Chen, X., Zhang, Y., Lin, L., Chen, Y., Shen, X., Huang, L., Zhao, F., & Yan, S. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01823-x · Cited by 2
Avaliação do tratamento clínico da doença de Graves
Peixoto, M. C., Coeli, C. M., & Vaisman, M. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000300013 · Cited by 2
Perricone, C., Versini, M., Ben-Ami, D., Gertel, S., Watad, ., Segel, M., Ceccarelli, F., Conti, F., Cantarini, L., Bogdanos, D. P., et al. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814307-0.00037-2 · Cited by 2
Evaluating the Thyroid Eye Disease Patient
Denisova, K., & Barmettler, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000351 · Cited by 3
Antithyroid Drug Therapy in Patients with Graves’ Disease
Laurberg, P., & Cooper, D. S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_6 · Cited by 2
Predictors of relapse in graves' hyperthyroidism after treatment with antithyroid drugs
Lawgaly, S. A., Kalousa, H. A., & Gerryo, S. E. (2018) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_75_18 · Cited by 2
Neset, M. T., Ulvik, A., Løvås, K., Laupsa‐Borge, J., Breivik, L., Stokland, A. M., Nedrebø, B. G., Rødahl, E., Husebye, E. S., Ueland, G. Å., et al. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0004 · Cited by 1
Self-citationHyperthyroidism Due to Graves‗ Disease – Is There an Optimal Pharmacological Treatment Regimen?
Bartalena, L. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.00.63 · Cited by 1
Hollander, J. M., & Davies, T. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4745-2.00012-2 · Cited by 1
Imam, S. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-25871-3_8 · Cited by 1
Aleksic, A., Aleksić, Ž., Manic, S., Mitov, V., & Jolić, A. (2014) · Medicinski pregled · doi:10.2298/mpns1410305a · Cited by 1
Risk factors influence on Graves' disease and Graves' ophthalmopathy
Medyczny, U., Czarnywojtek, A., Kurdybacha, P., Florek, E., Warmuz‐Stangierska, I., Walig, J., Rucha, M., Stangierski, A., & WOèNIAK, A. (2011) · Cited by 1
Treatment of relapsed hyperthyroidism
Chung, J. H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.4.248 · Cited by 1
Smoking and Prevention of Thyroid Eye Disease
Wiersinga, W. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1746-4_5
Djukić, A., Živančević-Simonović, S., Djurdjevic, P. M., & Arsenijević, N. (2006) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0608290d
Lima, N., Knobel, M., Camargo, R. Y., Tomimori, E. K., & Medeiros-Neto, G. A. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000400017
Aleksic, A., Aleksić, Ž., Manic, S., Mitov, V., Jolić, A., & Zdravkovic, K. (2014) · Timocki medicinski glasnik · doi:10.5937/tmg1404184a
perspectivas Anticorpos Anti-Tiróide: Aspectos Metodológicos e Importância Diagnóstica
Gilberto, J., Vieira, H., Kasamatsu, T. S., & Hauache, O. M. (2003)
Léger, J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4745-2.00011-0
Ekinci, İ., & Peynirci, H. (2020) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20203537
Panaitescu, A. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96245
DEMOGRAFINIŲ VEIKSNIŲ SĄSAJOS SU KLINIKINE GREIVSO LIGOS IŠRAIŠKA IR BAIGTIMI
Daukšienė, D., & Mickuvienė, N. (2013) · Sveikatos mokslai · doi:10.5200/sm-hs.2013.049
Relapse Rate and Clinical Risk Factors Affecting the Treatment of Graves’ Disease
Kiatpanabhikul, P. (2021) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.2021.59
Predictive Value of TRAb in the Early Drug Treatment of GD
陶, 玥. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1112862
Chng, C. L. (2018) · Springer eBooks · doi:10.1007/978-981-10-1124-5_2
Saller, B., & Janssen, O. E. (2006) · Springer eBooks · doi:10.1007/3-540-27385-9_60
Abd‐ElGawad, M., Abdelgalil, M. S., Abdelsattar, N. K., Salamah, H. M., & Kamel, M. A. (2023) · Research Square · doi:10.21203/rs.3.rs-3542960/v1
For Many Patients with Graves' Disease, It Is a Long Battle
Barbesino, G. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.450-452
Hyperthyroidism treatment: A brief review with recommendations
Abassi, W., Ouerghi, N., Jebabli, N., Feki, M., Bouassida, A., Weiss, K., & Knechtle, B. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100282
Management of Hyperthyroidism in Pregnancy
Gummalla, S., Kesara, M. R., & Maraka, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.017
Metadata
- Authors
- Nedrebo, B., Holm, P., Uhlving, S., Sorheim, J., Skeie, S., Eide, G., Husebye, E., Lien, E., & Aanderud, S.
- Affiliations
- University of Bergen (NO)
- Stord hospital (NO)
- Haukeland University Hospital (NO)
- ORCID
- Skeie, S
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 147
- Issue
- 5
- Pages
- 583-589
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2096392089
- Cited by
- 132
- References
- 29
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 10 · 2018: 10 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 8 · 2013: 8 · 2012: 4
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Helse Vest
- Norges Forskningsråd
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, relapse prevention, antithyroid drugs, levothyroxine, TSH receptor antibodies, smoking, goiter size, predictors of relapse
- MeSH terms
- Antibodies, Drug Combinations, Graves Disease, Humans, Prognosis, Prospective Studies, Receptors, Thyrotropin, Smoking, Antithyroid Agents, Thyroxine, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review